First Line Radiofrequency Ablation Versus Antiarrhythmic Drugs for Persistent Atrial Fibrillation Treatment (RAAFT-3)
Status:
Recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if catheter-based atrial fibrillation (AF) ablation
is superior to treatment with antiarrhythmic drugs as a first-line therapy for symptomatic
persistent AF.
Phase:
Phase 3
Details
Lead Sponsor:
University of Pennsylvania
Collaborators:
Biosense Webster, Inc. Texas Cardiac Arrhythmia Research Foundation